Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of LY3502970 in Fed and Fasted Healthy Participants
NCT05110794Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of orforglipron in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Concentration at Day 35, Area Under the Concentration-time Curve From 0 to 24 Hour and 1 more. Started Nov 2021; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05110794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05110794.